 |
|
Thyroglobulin Assays in the Postoperative Management of Differentiated Thyroid Cancer
CDR Earl H. Harley, MC;
CAPT Richard G. Daly, MC;
John W. Hodge, MC
Arch Otolaryngol Head Neck Surg. 1988;114(3):333-335.
Abstract
• Carcinoma of the thyroid gland is the most common endocrine malignancy managed by the head and neck surgeon. Accepted therapy for differentiated macroscopic (>1 to 1.5 cm) lesions is total or near-total thyroidectomy, followed by radioactive iodine treatment. Followup care usually consists of annual total body scan to rule out the presence of metastatic disease. Thyroglobulin, which is elaborated only by thyroid cells, either normal or metastatic, serves as a tumor marker when all functioning tissue has been ablated. The routine use of thyroglobulin assays obviates the expense and inconvenience of an annual scan. This article reviews the usefulness and limitations of serum radioimmune assays in the postoperative management of differentiated thyroid cancer. We also present several representative cases treated at our institution.
(Arch Otolaryngol Head Neck Surg 1988;114:333-335)
Author Affiliations
USN; USN; USN
From the Department of Otolaryngology—Head and Neck Surgery (Dr Harley), and Internal Medicine-Endocrinology Division (Drs Daly and Hodge), Clinical Investigation Department, Naval Hospital, San Diego.
Footnotes
Accepted for publication July 2, 1987.
The views expressed herein are those of the authors and are not to be construed as official, or as reflecting the views of the US Navy or the Department of Defense.
Read before the Annual Meeting of the Southern California Chapter of the American College of Surgeons, Santa Barbara, Calif, Jan 17, 1987.
Reprint requests to Clinical Investigation Department, Naval Hospital, San Diego, CA 92134-5000 (Dr Harley).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
